Compare FSLR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLR | INSM |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 30.1B |
| IPO Year | 2006 | 2000 |
| Metric | FSLR | INSM |
|---|---|---|
| Price | $198.12 | $144.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 24 |
| Target Price | ★ $241.42 | $190.43 |
| AVG Volume (30 Days) | ★ 2.1M | 2.0M |
| Earning Date | 06-01-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.22 | N/A |
| EPS | ★ 14.21 | N/A |
| Revenue | ★ $5,219,376,000.00 | N/A |
| Revenue This Year | $4.13 | $168.46 |
| Revenue Next Year | $15.23 | $65.97 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | ★ 24.09 | N/A |
| 52 Week Low | $116.56 | $60.40 |
| 52 Week High | $285.99 | $212.75 |
| Indicator | FSLR | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 43.95 |
| Support Level | $196.80 | $142.99 |
| Resistance Level | $250.73 | $149.08 |
| Average True Range (ATR) | 6.16 | 4.08 |
| MACD | 1.13 | 0.37 |
| Stochastic Oscillator | 70.13 | 54.84 |
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.